Yangtze River's exclusive review injection meets its rivals! 13 pharmaceutical companies including Shisiyao speed up food rush

Figure 1: Shijiazhuang four drugs of hydrochloric acid right-mememided injection declarationsource: CDE official websiteFigure 2: hydrochloric acid right-memeding injection TOP3 enterprise market sharesource: Minnet China public medical institutions terminal competition pattern
hydrochloric acid right mememided injection is a heavy variety of mental stabilization drugs, minnet data data, 2019 in China's public hospitals, urban public hospitals, urban public hospitalsJune 2018, Yangzijiang's hydrochloric acid right-metomidin injection 3 imitation of the listing application was approved for production, and treated as the same evaluation, and then the exclusive winning bid "4 plus 7" collection, alliance area collection, TOP3 enterprise market share was greatly shuffledIn 2019, the market share of the leading company Hengrui fell sharply to 53.21%, Enwar declined to TOP3 but the market share was reduced to 6.46%, and top2 enterprises from the top of the Yangzi River, with sales of 1.186 billion yuan, a growth rate of 1814.75%Table 1: Hydrochloric acid right-to-to-injection injection 3 types of imitation and consistency evaluation in the review of thesource: MED China Drug Review Database 2.0so far, in addition to Shijiazhuang four drugs to be accepted by CDE, there are Five types of generic listing applications such as Nanjing Zhengda Tianqing Pharmaceuticals in the review approval, in addition, Hengrui, Enhua and other 7 consistent evaluation supplementis are also in the review.